New First-Line Strategies in HER2+ Metastatic Breast Cancer – Dr. Mark Pegram & Dr. Carol Tweed

Recorded live around the latest data from SABCS, ASCO, and ESMO, this in-depth conversation features Dr. Mark Pegram and Dr. Carol Tweed examining whether the long-standing Cleopatra regimen is finally giving way to a new first-line standard in HER2-positive metastatic breast cancer.

From Destiny-Breast09 and unprecedented progression-free survival results to response depth, CNS considerations, and the real-world implications of continuous ADC therapy, this discussion breaks down what the data truly mean for patient care.

The conversation also explores induction vs. maintenance strategies, the role of endocrine therapy and CDK4/6 inhibitors, quality-of-life tradeoffs, pneumonitis risk, and how clinicians are navigating shared decision-making in an era of rapidly evolving options.

A must-watch episode for oncologists preparing for what may be the biggest first-line shift in HER2-positive metastatic disease in over a decade.